TLR2 and lymphoma: Another ligand for TLR2, Hsp72, has also proven to activate and increase the suppressive capacities of MDSCs in murine lymphoma, mammary carcinoma and colon carcinoma models, and showed relevance in humans as the human tumor cell line TDE triggered the suppressive function of MDSCs in a Hsp72 dependent manner (240).